Roelof Botha Buys Shares of Natera, Inc. (NTRA)

Roelof Botha made headlines with his recent purchase of 1,691 shares of Natera, Inc. (NasdaqGS: NTRA) on June 26, 2026. This acquisition signals his confidence in the company amidst its growth in the diagnostics and research sector.

Insider Buying and Selling at Natera, Inc.

Roelof Botha wasn't the only insider showing interest in Natera, Inc. on June 26, 2026. Other insiders like Baynes Roy, Eric Rubin, and Thomas Lynch Jr. also bought shares, with transactions not planned under Rule 10b5-1. These purchases highlight a noteworthy insider activity day for Natera.

Other Institutional Activity in Natera, Inc.

JPMorgan Chase & Co. increased its holdings by 532,333 shares, reaching a total of 13,386,667 shares valued at about $2.5 billion, marking a 4.1% rise. Price T Rowe Associates Inc. also boosted its position by 1,312,887 shares, totaling 12,184,876 shares worth $2.4 billion, a 12.1% increase. Meanwhile, BlackRock, Inc. trimmed its stake by 182,103 shares, bringing its total to 10,677,338 shares valued at approximately $2.1 billion, a 1.7% decrease. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions with 6,008,496 shares and 5,644,695 shares, respectively.

Natera, Inc. Stock Down 17.1%

Shares of Natera, Inc. traded near $267.05 on Wednesday. The company has a market cap of $37.5 billion, with a forward P/E ratio that is not meaningful due to a lack of profitability. Natera's stock has a 52-week low of $131.81 and a high of $271.47. Its 50-day moving average is $212.40, and the 200-day moving average stands at $208.58. The company maintains a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Recent Earnings

Natera reported revenue of $2.5 billion, showing a growth of 38.8%. However, the company posted a net margin of -9%, reflecting ongoing challenges in reaching profitability. Its return on equity was -15%. Investors are looking forward to the next earnings report scheduled for August 6, 2026.

Analysts Set New Price Targets

Several analysts have set new price targets for Natera, Inc. On June 29, 2026, Guggenheim maintained its 'buy' rating with a $290 price target. Bernstein reiterated its 'buy' rating with a $310 target on June 26, 2026. BTIG and Barclays both maintained 'buy' ratings with targets of $275 and $260, respectively. The consensus among analysts is strong, with a mean price target of $262.67 based on 21 opinions, reinforcing a 'strong buy' recommendation.

About Natera, Inc.

Natera, Inc. is a healthcare company specializing in diagnostics and research. Based in Austin, Texas, it offers a range of molecular testing services, including personalized ctDNA blood tests for cancer monitoring and non-invasive prenatal tests. The company, led by CEO Steven Leonard Chapman, employs over 6,000 people and collaborates with various laboratories and pharmaceutical companies globally.

Bottom Line

Roelof Botha's share purchase adds to the positive sentiment around Natera, Inc., a company known for its innovative testing services. While the company faces challenges in achieving profitability, its strong market position and insider confidence are noteworthy. Keep in mind that this insider activity reflects past events and doesn't necessarily indicate future performance.